134 related articles for article (PubMed ID: 37949486)
1. Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis.
Kim JH; Cho HW; Park EY; Han KH; Kim ET; Lee JK; Park SY; Armbrust R; Fotopoulou C; Lim MC
Int J Gynecol Cancer; 2023 Dec; 33(12):1913-1920. PubMed ID: 37949486
[TBL] [Abstract][Full Text] [Related]
2. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
[TBL] [Abstract][Full Text] [Related]
3. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B; Colomban O; Heywood M; Lee C; Davy M; Reed N; Pignata S; Varsellona N; Emons G; Rehman K; Steffensen KD; Reinthaller A; Pujade-Lauraine E; Oza A
Gynecol Oncol; 2013 Aug; 130(2):289-94. PubMed ID: 23694718
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
[TBL] [Abstract][Full Text] [Related]
5. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
[TBL] [Abstract][Full Text] [Related]
6. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
[TBL] [Abstract][Full Text] [Related]
7. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
[TBL] [Abstract][Full Text] [Related]
8. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
10. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
11. CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer.
Liao YC; Ou YC; Wu CH; Fu HC; Tsai CC; Lin H
Cancer Biomark; 2021; 32(4):559-567. PubMed ID: 34397404
[TBL] [Abstract][Full Text] [Related]
12. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
13. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Colomban O; Clamp A; Cook A; McNeish IA; You B
JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 Jan; ():. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer.
Colaković S; Lukiç V; Mitroviç L; Jeliç S; Susnjar S; Marinkoviç J
Int J Biol Markers; 2000; 15(2):147-52. PubMed ID: 10883888
[TBL] [Abstract][Full Text] [Related]
16. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
17. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
Gronlund B; Hansen HH; Høgdall C; Høgdall EV; Engelholm SA
Br J Cancer; 2004 Jan; 90(2):377-82. PubMed ID: 14735180
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
19. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
20. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]